Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

86.27 -2.11 (-2.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 994,687
Open 87.78
Bid (Size) 84.75 (1)
Ask (Size) 87.88 (1)
Prev. Close 88.38
Today's Range 86.19 - 88.24
52wk Range 80.53 - 117.77
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga

Performance

YTD
-14.25%
-14.25%
1 Month
-4.01%
-4.01%
3 Month
-10.45%
-10.45%
6 Month
-4.23%
-4.23%
1 Year
-0.79%
-0.79%

More News

Read More
What 16 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
Earnings Outlook For Biomarin Pharmaceutical
Via Benzinga
What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
What 13 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Via Investor's Business Daily
Exposures Product Safety
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Via The Motley Fool
Topics Stocks
Exposures US Equities
4 Unforgettable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Via The Motley Fool
Topics Stocks
Exposures US Equities
Biomarin's Q2 Beat Street View, Raises Voxzogo Annual Guidance Driven By Global Demand
Via Benzinga
3 Biotech Stocks to Make Your ‘Get Rich’ Dreams Come True
Via InvestorPlace
What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
Earnings Scheduled For July 31, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
Via Benzinga
Is BioMarin Ready To Rebound After FDA Approval Of Roctavian?
Via MarketBeat
Exposures Product Safety
BioMarin Presents ~20% Upside Amid Voxzogo's Success and Slow Roctavian Uptake, Analyst Says
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023
Via Benzinga
BioMarin's Roctavian US Launch: Focus on Commercial Strategy Amid EU Failures, Analyst Points Out
Via Benzinga
Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories
Via Benzinga
BioMarin's Delayed Roctavian Scores FDA Nod As First Hemophilia A Gene Therapy In US
Via Benzinga
NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday
Via Benzinga
3 Biotech Stocks to Buy With Explosive Upside Potential
Via InvestorPlace
NASDAQ: BMRN Long Term Investor Notice: Lawsuit Against Directors at BioMarin Pharmaceutical Inc. Filed
Via SBWire
3 Biotech Stocks That Could Skyrocket in the Next 12 Months
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.